Failure to Achieve a PSA Level ≤1 ng/mL After Neoadjuvant LHRHa Therapy Predicts for Lower Biochemical Control Rate and Overall Survival in Localized Prostate Cancer Treated With Radiotherapy-Reference-Cited by-同舟云学术

Failure to Achieve a PSA Level ≤1 ng/mL After Neoadjuvant LHRHa Therapy Predicts for Lower Biochemical Control Rate and Overall Survival in Localized Prostate Cancer Treated With Radiotherapy

Published:2007-12 Issue:5 Volume:69 Page:1467-1471
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Mitchell Darren M.,McAleese Jonathan,Park Richard M.,Stewart David P.,Stranex Stephen,Eakin Ruth L.,Houston Russell F.,O'Sullivan Joe M.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference18 articles.

1. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate;Pilepich;Int J Radiat Oncol Biol Phys,2001

2. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02;Hanks;J Clin Oncol,2003

3. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial;D'Amico;JAMA,2004

4. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression;Roach;J Clin Oncol,2003

5. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T l-2 adenocarcinoma of the prostate;Zietman;Radiother Oncol,1996

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer;Frontiers in Oncology;2023-10-17

2. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy;European Journal of Nuclear Medicine and Molecular Imaging;2023-07-05

3. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials;International Journal of Radiation Oncology*Biology*Physics;2019-08

4. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer;Prostate Cancer and Prostatic Diseases;2017-01-17

5. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges;Prostate Cancer and Prostatic Diseases;2016-05-03